Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

5.460 +0.030 (+0.55%)
Streaming Delayed Price Updated: 2:39 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CytomX Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q3 2025 Earnings Miss, Stock Falls ↗
CytomX Therapeutics Q3 2025 earnings miss analyst estimates for revenue and EPS, triggering a negative market reaction. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Why CytomX Therapeutics Stock Was Skyrocketing This Week ↗
One pundit believes the company might have a winning cancer drug in its pipeline. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
CytomX (CTMX) Q2 Revenue Drops 26% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS ↗
CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism. 
Via Chartmill
News headline image
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
News headline image
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - A Strong Contender in High-Growth Biotech ↗
CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
News headline image
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug ↗
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses. 
Via Stocktwits
News headline image
Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Monday's session: most active stocks ↗
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
News headline image
Stocks Under $1 to Watch: TAOP, WLGS, HIT, CTMX, JYD – Major Updates, Earnings & Offerings, More Inside….
Via AB Newswire
Topics Economy
News headline image
Which stocks are moving on Monday? ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report ↗
CytomX reported early Phase 1 data for CX-2051 in advanced colorectal cancer, with a 94% disease control rate. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.